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In atherosclerosis, serum lipoproteins, particu-
larly low density lipoprotein (LDL), accumulate 
in the arterial intima through binding to matrix 
proteoglycans (Skålén et al., 2002) and undergo 
oxidative modification. Blood monocytes are re-
cruited into these regions of the intima, differen-
tiate into macrophages or DCs, and internalize 
oxidatively modified lipoproteins via scavenger 
receptors or by macropinocytosis (for review see 
Moore and Freeman, 2006). BM-derived cells 
accumulate in early mouse atherosclerotic lesions 
(Mullick et al., 2008), and monocyte recruit-
ment persists in advanced lesions (Swirski et al., 
2006; Tacke et al., 2007).
Circulating monocytes consist of at least 
two subpopulations, with distinct expression   
of cell-surface markers, chemokine receptors, 
and functions during inflammatory responses 
(Grage-Griebenow et al., 2001; Geissmann   
et al., 2003). In mice, the Ly-6Chigh subset is 
elevated  during  hypercholesterolemia  and  is 
preferentially recruited to atherosclerotic le-
sions (Swirski et al., 2007; Tacke et al., 2007). 
Ly-6Chigh  monocytes  express  abundant  L-
  selectin and multiple chemokine receptors, 
including CCR2, but relatively low levels of 
CX3CR1. Ly-6Clow monocytes express higher 
levels of CX3CR1, and low to nondetectable 
levels of most chemokine receptors, L-selectin 
and Ly-6C. Thus, it is intriguing that recruit-
ment of Ly-6Chigh monocytes to lesions is de-
pendent on CCR2, CCR5, and CX3CR1, 
whereas recruitment of Ly-6Clow monocytes is 
independent of CX3CR1 and dependent on 
CCR5, which is up-regulated in hypercholes-
terolemic mice (Tacke et al., 2007).
Fatty streaks are composed almost entirely 
of myeloid foam cells, and their formation and 
lateral expansion are critically dependent on 
monocytes/macrophages. This was demon-
strated using osteopetrotic mice that have a point 
mutation that disrupts M-CSF and are defi-
cient in circulating monocytes, tissue macro-
phages, and osteoclasts. Osteopetrotic mice are 
highly protected from atherosclerosis in the 
setting of hypercholesterolemia (Smith et al., 
1995; Qiao et al., 1997), and these studies im-
plicate  monocytes  and  their  progeny  as  key 
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The contribution of intimal cell proliferation to the formation of early atherosclerotic 
lesions is poorly understood. We combined 5-bromo-2’-deoxyuridine pulse labeling with 
sensitive en face immunoconfocal microscopy analysis, and quantified intimal cell prolifera-
tion and Ly-6Chigh monocyte recruitment in low density lipoprotein receptor–null mice. Cell 
proliferation begins in nascent lesions preferentially at their periphery, and proliferating 
cells accumulate in lesions over time. Although intimal cell proliferation increases in paral-
lel to monocyte recruitment as lesions grow, proliferation continues when monocyte re-
cruitment is inhibited. The majority of proliferating intimal cells are dendritic cells 
expressing CD11c and major histocompatibility complex class II and 33D1, but not CD11b. 
Systemic injection of granulocyte/macrophage colony-stimulating factor (GM-CSF) mark-
edly increased cell proliferation in early lesions, whereas function-blocking anti–GM-CSF 
antibody inhibited proliferation. These findings establish GM-CSF as a key regulator of 
intimal cell proliferation in lesions, and demonstrate that both proliferation and monocyte 
recruitment contribute to the inception of atherosclerosis.
© 2009 Zhu et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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ing Ly-6Chigh monocytes, which are preferentially recruited 
to plaques (Swirski et al., 2007; Tacke et al., 2007). The 
effects of short-term hypercholesterolemia on monocyte 
release from the BM and circulating monocyte levels is   
unknown.  We  fed  LDL  receptor–null  (Ldlr/)  mice  a 
cholesterol-rich diet (CRD) for just 2 wk and found that   
the number of Ly-6Chigh blood monocytes was increased 
2.9-fold (Fig. 1 d). In contrast, circulating Ly-6Cneg monocytes 
were  not  significantly  increased  by  hypercholesterolemia 
(Fig. 1 d). There was a trend toward higher BrdU labeling 
of Ly-6Chigh blood monocytes at 12, 18, and 24 h in hyper-
cholesterolemic mice, and a statistically significant difference   
(P < 0.03) between hypercholesterolemic and normocholester-
olemic mice was found when data from these time points were 
combined (Fig. 1 e).
Proliferation of intimal leukocytes increases progressively 
from the inception of atherosclerosis in parallel  
to recruitment of BM-derived Ly-6Chigh monocytes
Feeding Ldlr/ mice a CRD initiates a marked hypercho-
lesterolemia and atherosclerotic lesion formation through-
out the aorta (Ishibashi et al., 1994a; Lichtman et al., 1999). 
As early as 1 wk after CRD feeding, nascent lesions were 
detected in the lesser curvature (LC) of the Ldlr/ ascend-
ing  aorta,  and  lesion  surface  area  increased  progressively 
with time (Fig. 2 a). Cell proliferation in the ascending aor-
tic intima was examined 2 h after injection of BrdU, a time 
point when BrdU+ monocytes were not detected in the cir-
culation (Fig. 1 e). BrdU+ nuclei were also quantified 24 h 
after BrdU injection when proliferating intimal cells as well 
as BM-derived BrdU-labeled Ly-6Chigh monocytes recruited 
from  the  blood  are  detected.  As  we  reported  previously 
(Jongstra-Bilen et al., 2006), in the ascending aorta of nor-
mal C57BL/6 mice (Ldlr+/+), we found very low prolifera-
tion at 2 h only in the LC (0.5 BrdU+ nuclei; Fig. 2 b). At 
24 h, BrdU+ nuclei increased by 20-fold to 10.3 ± 2.3 nu-
clei, which represents mostly recruited BrdU-labeled Ly-6Chigh 
monocytes  and  is  consistent  with  our  previous  findings 
(Jongstra-Bilen et al., 2006). In Ldlr/ mice fed a standard 
chow diet (SCD; Fig. 2 b, time point 0), the numbers of 
BrdU+ nuclei at 2 and 24 h were virtually identical to wild-
type C57BL/6 mice (0.5 ± 0.3 and 10 ± 2, respectively), 
indicating relatively comparable baseline rates of cell pro-
liferation and monocyte recruitment to the intima. After 
switching Ldlr/ mice to a CRD, the number of BrdU+ 
nuclei at 2 and 24 h progressively increased, which demon-
strates a parallel increase in both intimal cell proliferation 
and monocyte recruitment from the inception of athero-
sclerosis. At 2 wk of CRD, intimal cell proliferation in-
creased by 40-fold relative to C57BL/6 and Ldlr/ mice 
fed a SCD, and the abundance of BrdU+ nuclei detected at 
24 h increased by approximately 8-fold.
All BrdU+ nuclei were located in the LC (Fig. 2, d and e) 
and many (88 ± 4% and 66 ± 12% at 2 and 24 h, respec-
tively) were at borders of lesions (Fig. 2, c and d), suggest-
ing that cell proliferation and monocyte recruitment occur 
cells in lesion development. In contrast to M-CSF, defi-
ciency of GM-CSF has no significant effects on circulating 
monocytes  or  tissue  macrophages,  and  variable  effects  on 
mouse atherosclerotic lesion formation (Ditiatkovski et al., 
2006; Shaposhnik et al., 2007). An interesting feature in the 
setting of GM-CSF deficiency is a decrease of CD11c+ cells 
in lesions (Shaposhnik et al., 2007).
The biology of macrophages and DCs in atherosclerotic 
lesions is complex. These cells can proliferate or undergo 
apoptosis, and both processes have been observed primarily in 
advanced  human  and  experimental  lesions  (Rosenfeld  and 
Ross, 1990; Orekhov et al., 1998; Merched et al., 2003) and 
in a vascular occlusion model in hypercholesterolemic apolipo-
protein E–deficient (Apoe/) mice (Lessner et al., 2002). 
The prevailing opinion is that monocyte recruitment accounts 
for the formation of early lesions, and the relationship of pro-
liferation to monocyte recruitment is not understood. A key 
impediment has been the lack of a sensitive approach to study 
cell proliferation and monocyte recruitment in early lesions. 
We used BrdU pulse labeling combined with en face confocal 
microscopy of the mouse aorta to detect cell proliferation and 
Ly-6Chigh monocyte recruitment, and localize them with re-
spect to lipid accumulation in the intima. We found that inti-
mal cell proliferation begins in nascent lesions preferentially at 
the periphery, increases as lesions progress in parallel to mono-
cyte recruitment, primarily involves DCs, and is dependent 
on GM-CSF but not monocyte recruitment.
RESULTS AND DISCUSSION
BrdU pulse labeling preferentially labels Ly-6Chigh  
blood monocytes
BrdU is stably incorporated into the DNA of cells during the 
S phase of the cell cycle. Pulse labeling is achieved because 
injected BrdU is cleared from the plasma within hours (Kriss 
and Revesz, 1962). BrdU labels proliferating monocyte pre-
cursors in the BM, and labeled monocytes appear in the cir-
culation after 4–6 h (Goto et al., 2003; Jongstra-Bilen et al., 
2006). We used flow cytometry to investigate BrdU labeling 
of BM and blood monocyte subsets in wild-type C57BL/6 
mice (Fig. 1 a). BrdU+ Ly-6ChighCD115high cells were de-
tected in the BM at 2 h, increased, and reached a plateau at 12 h 
(Fig. 1 b). In the blood, BrdU+ Ly-6Chigh monocytes were 
not detected within 6 h but increased rapidly thereafter and 
reached a plateau at 12–24 h (Fig. 1 b), at which time 35–45% 
of  circulating  blood  Ly-6Chigh  monocytes  were  BrdU+. 
Ly-6CnegCD115high BM cells and blood monocytes did not stain 
for BrdU. The mean fluorescence intensity (MFI) of BM 
BrdU-labeled Ly-6ChighCD115high cells declined over time, 
consistent with ongoing rapid proliferation of monocyte pre-
cursors (Fig. 1 c). In contrast, the MFI of BrdU+ Ly-6Chigh 
blood monocytes remained relatively stable over 24 h.
Wild-type mice are resistant to developing diet-induced 
hypercholesterolemia and atherosclerosis. In atherosclerosis-
susceptible Apoe/ mice, prolonged and marked hypercho-
lesterolemia as a result of feeding a high fat diet for 12–25 
wk induced a substantial increase in the number of circulat-JEM VOL. 206, September 28, 2009  2143
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Figure 1.  Analysis of BrdU pulse-labeled monocyte subpopulations in the BM and blood using flow cytometry. (a, left) A dot plot of a blood 
sample from a C57BL/6 mouse obtained 18 h after BrdU injection illustrates identification of monocyte subsets. Typically, >85% of events were gated in 
forward versus side scatter analysis (not depicted). Monocytes expressed high levels of CD115+, and subpopulations were identified based on high, low, 
and negative (neg) expression levels of Ly-6C. Neutrophils (N), expressing low levels of CD115 and intermediate levels of Ly-6C, served as a landmark for 
setting the Ly-6Chigh gate. (right) A histogram of BrdU fluorescence gated on the Ly-6Chigh cells indicated that 50.6% were BrdU+. Representative data 
from one out of three independent experiments is shown. (b) The percentages of BrdU+ Ly-6Chigh and Ly-6Cneg monocytes in the BM (left) and blood 
(right) of C57BL/6 mice are plotted at different time points after BrdU injection. (c) A time course shows the MFI of BrdU+ Ly-6Chigh monocytes in the BM 
and blood. In b and c, three independent experiments were performed and means ± SEM were derived from three mice per time point. (d) The absolute 
numbers of Ly-6Chigh and Ly-6Cneg monocytes in the blood of C57BL/6 mice and Ldlr/ mice fed a CRD for 2 wk are plotted. They were derived from total 
blood leukocyte counts, and the percentage of each monocyte subpopulation was determined by flow cytometry. The total blood leukocyte count was 
elevated 1.5-fold in Ldlr/ relative to C57BL/6 mice (8.94 ± 0.75 vs. 5.8 ± 0.38 × 106 cells/ml; three and two independent experiments, respectively). 
Means ± SEM were derived from eight mice per genotype (*, P < 0.005). (e) Percentage of BrdU+ Ly-6Chigh monocytes in the blood after BrdU pulse label-
ing of C57BL/6 mice and Ldlr/ mice fed a CRD for 2 wk (three independent experiments for each genotype with means ± SEM derived from three mice 
per time point). The asterisk indicates a statistically significant difference (P < 0.03) between hypercholesterolemic and normocholesterolemic mice when 
data from the 12, 18, and 24 h time points were combined (53.3 ± 3.2% vs. 38.5 ± 4.8%).
in similar regions. Proliferating intimal cells at borders of 
lesions were often adjacent to cells containing lipid drop-
lets, and their nuclei extended below the endothelial cell 
monolayer (Fig. S1, a–c).
Proliferating intimal cells accumulate  
in 2-wk atherosclerotic lesions
BrdU labeling in lesions was initially studied within 6 h of BrdU 
injection, when minimal BrdU+ monocytes are released from 2144 CELL PROLIFERATION DURING ATHEROGENESIS | Zhu et al.
Consistent with this, BrdU+ nuclear doublets that likely repre-
sent daughter cells also increased within 3 h (Fig. S1, e and f).
Proliferating  intimal  cells  may  divide  to  produce  two 
daughter cells or, alternatively, may undergo apoptosis. The 
the BM (Fig. 1 e). Intimal BrdU+ nuclei were detected at 1 h, 
increased at 2 and 3 h, and then remained stable (Fig. S1 d). This 
suggests that the BrdU labeling window is <3 h. Another possi-
bility is that labeled intimal cells complete mitosis within 3 h. 
Figure 2.  Quantification of lipid accumulation, intimal cell proliferation, and monocyte recruitment during the initiation of atherosclerosis. 
(a) En face fluorescent images of ascending aortas from Ldlr/ mice fed a CRD for 1, 2, or 3 wk. Intimal lipid accumulation was visualized (red; top), and 
the lesion areas relative to the value for the 3-wk CRD group (dashed line) were determined (bottom). Means ± SEM were derived from 4 (1 wk), 22 (2 wk), 
and 6 (3 wk) mice studied in 2, 11, and 3 independent experiments, respectively. A representative image is shown for each time point. Note that lipid 
accumulation was detected in the LC but not in the GC, or in Ldlr/ mice fed SCD (not depicted). (b) Intimal BrdU+ nuclei were enumerated at 2 and 24 h 
after BrdU pulse labeling in C57BL/6 mice (Ldlr+/+) fed SCD or Ldlr/ mice fed a CRD (0–3 wk). The entire surface of the ascending aorta above the aortic 
valve was scanned by en face confocal microscopy, but BrdU+ nuclei were detected only in the LC. For each time point, four to seven independent experi-
ments were performed, and means ± SEM were derived from four to seven mice (*, P < 0.05; **, P < 0.01 relative to Ldlr/ mice fed SCD, i.e., 0 wk of 
CRD). (c) A composite of en face images taken with a 16× objective shows the entire oil red O–stained lesion area (red) in the LC of the ascending aortic 
arch harvested from an Ldlr/ mouse that was fed a CRD for 2 wk and pulsed for 2 h with BrdU. BrdU+ nuclei (green) are primarily at the periphery of 
the lesion. Inset (top left) shows a high power image of the region indicated with dashed lines. Nuclei are blue. (d and e) En face confocal images of the 
ascending aortic arch harvested from an Ldlr/ mouse fed CRD for 2 wk and pulsed with BrdU for 24 h. BrdU+ nuclei and lipid accumulated in the LC (d) 
but not in the GC (e). Images in c, d, and e are representative of at least four independent experiments. Bars: (a) 1 mm; (c–e) 20 µm.JEM VOL. 206, September 28, 2009  2145
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fate of proliferating intimal cells was investigated by inhibiting 
blood monocyte recruitment with pertussis toxin (PTx). PTx 
inactivates Gi chemokine receptors and has been used in 
vivo to study the contribution of chemokine receptors versus 
E-selectin–triggered integrin activation in neutrophil recruit-
ment to the inflamed peritoneal cavity (Smith et al., 2004). 
We found that PTx markedly diminished monocyte recruit-
ment at 24 h to thioglycollate-inflamed peritoneal cavity de-
spite a marked increase in circulating myeloid cells (Fig. 3 a 
and Fig. S2). In contrast, PTx reduced but did not eliminate 
neutrophil recruitment, consistent with a previous report 
(Smith et al., 2004). These data illustrate an important differ-
ence in monocytes versus neutrophil signaling. As was shown 
previously, neutrophil binding to E-selectin induces a com-
pensatory signaling pathway that bypasses Gi signaling irre-
versibly blocked by PTx, whereas our data suggest that this 
compensatory pathway is not operative in monocytes.
In Ldlr/ mice fed a CRD for 2 wk, PTx significantly 
diminished the number of BrdU+ nuclei at 24 h from 86 ± 
10 to 26 ± 12 (Fig. 3 b), consistent with PTx blockade of 
monocyte  recruitment.  In  a  parallel  experiment,  21  ±  2 
BrdU+ nuclei representing intimal cells were detected at 2 h. 
Comparable BrdU+ nuclei (26 ± 12) were detected in the 
PTx experiment at 24 h, suggesting that proliferating intimal 
cells persist and accumulate in lesions.
Intimal cell proliferation is independent  
of monocyte recruitment
Intimal cell proliferation in 2-wk lesions was determined by 
2-h BrdU labeling after inhibition of monocyte recruitment 
for 22 or 46 h with PTx. Proliferation was not decreased by 
PTx at 22–24 h and, in fact, increased at 46–48 h (Fig. 3 c), 
which may represent a compensatory increase in cell prolif-
eration in response to diminished blood monocyte recruit-
ment. These data reveal that proliferating intimal cells are not 
newly recruited blood monocytes.
Proliferating intimal cells express DC markers
Immunostaining  for  various  leukocyte  markers  was  per-
formed to determine the phenotype of BrdU+ cells in athero-
sclerotic lesions. The majority of foam cells in 2-wk lesions 
are CD11c+ and CD68+, whereas CD11b+ cells are located 
in clusters (Fig. S3). After 2 or 24 h of BrdU labeling, >90% 
of  BrdU+  cells  expressed  CD45,  a  pan-leukocyte  marker 
(Fig. 4 b). BrdU+ cells costained predominantly with CD11b 
24 h after labeling (Fig. 4, a and b), consistent with recruit-
ment to lesions of Ly-6Chigh blood monocytes, which are 
CD11b+. More than 90% of proliferating cells (2 h of BrdU 
labeling) costained for CD11c, a DC marker, and >60% of 
BrdU+ cells expressed CD11c at 24 h, consistent with sur-
vival of proliferating CD11c+ cells.
Figure 3.  PTx blockade of monocyte recruitment reveals that pro-
liferating intimal cells accumulate in 2-wk lesions, and intimal cell 
proliferation is independent of monocyte recruitment. (a) Flow 
cytometry plots of peritoneal exudate cells harvested 24 h after i.p. thio-
glycollate injection of control and PTx-treated mice (percentages are 
indicated). Representative data from five mice per group studied in two 
independent experiments are shown. Additional details are provided in 
Fig. S2. (b) Ldlr/ mice fed a CRD for 2 wk were injected with BrdU at 2 h 
before treatment with PTx or PBS (C, control). Aortas were harvested 24 h 
(left) and 2 h (right) after BrdU injection, and BrdU+ nuclei were enumer-
ated. (c) Ldlr/ mice fed a CRD for 2 wk were injected with PTx, and BrdU 
pulse labeling was performed 22 or 46 h later. Aortas were harvested after 
2 h, and BrdU+ nuclei were enumerated. In b and c, four independent 
experiments were performed at each time point, and means ± SEM were 
derived from four mice per group. *, P < 0.05 relative to C; **, P < 0.01.
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Figure 4.  Expression of leukocyte markers by BrdU+ cells in early atherosclerotic lesions. (a and b) Ldlr/ mice fed a CRD for 2 wk were injected 
with BrdU at 2 or 24 h before harvesting of the ascending aorta. (a) Immunostaining for BrdU (green) was performed in conjunction with CD11b (red), 
CD11c (red), or CD45 (not depicted), and tissues were examined by en face confocal microscopy. Nuclei are blue. Arrowheads indicate representative 
BrdU+ cells that costained with CD11b or CD11c (closed) and those that were not costained (open). (b) Quantitative analysis of BrdU+ intimal cells that JEM VOL. 206, September 28, 2009  2147
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costained with CD45, CD11b, or CD11c at 2 and 24 h after labeling. Data are expressed as the percentage of total BrdU+ cells. (c and d) Ldlr/ mice fed a 
CRD for 2 wk were injected with BrdU 2 h before harvesting of the ascending aorta. (c) Immunostaining for BrdU (green) and CD11c (yellow) was per-
formed in conjunction with CD11b, CD68, or MHC II (red). Closed arrowheads indicate BrdU+ cells that costained with CD11c and CD11b, CD68, or MHC II; 
open arrowheads indicate BrdU+ cells costained only with CD11c. (d) Quantitative analysis of BrdU+ intimal cells that costained with the indicated mark-
ers. (e) Images of the ascending arch LC from normal C57BL/6 mice costained for CD11c (green) and 33D1 (red; arrowheads). (f) Images of the ascending 
arch LC from Ldlr/ mice fed a CRD for 2 wk and injected with BrdU at 2 h before harvesting costained for BrdU (green), CD11c (yellow), and 33D1 (red; 
arrowheads). All images are representative of four independent experiments. In b and d, means ± SEM of four independent experiments are plotted (four 
mice per group; **, P < 0.01; ***, P < 0.001). Bars, 20 µm.
 
The expression of additional myeloid and DC markers by 
proliferating cells in 2-wk lesions was evaluated. 2 h after BrdU 
labeling, most BrdU+CD11c+ cells costained with CD68, a 
marker expressed by monocytes, macrophages, and DCs (Fig. 4, 
c and d; and Fig. S4). Relatively low costaining with CD11b+ 
was  confirmed.  Many  BrdU+CD11c+  cells  costained  with 
MHC class II (MHC II; Fig. 4, c and d; and Fig. S4), which is 
expressed by DCs, and with 33D1 (Fig. 4 f), a mAb that spe-
cifically targets mouse DCs (Nussenzweig et al., 1982; Xu   
et al., 2007). 33D1 stained resident intimal DCs in the normal 
mouse aorta (Fig. 4 e). Collectively, our data indicate that the 
majority of proliferating intimal cells in early atherosclerotic 
lesions express DC markers and, thus, may be capable of DC 
functions analogous to intimal DCs in the normal intima (Choi 
et al., 2009). Proliferating cells in early lesions may originate 
from intimal DCs residing in atherosclerosis-predisposed re-
gions of the normal intima (Jongstra-Bilen et al., 2006; Choi 
et al., 2009) and/or recruited monocytes that differentiated in 
lesions to express DC markers after several days.
GM-CSF is a critical regulator of cell proliferation  
in early atherosclerotic lesions
GM-CSF is a myeloid growth factor that induces DC differ-
entiation from BM precursors and monocytes, and regulates the 
properties of mature myeloid cells in inflammation (Hamilton 
and Anderson, 2004). Modified LDL induces endothelial cell 
expression  of  GM-CSF  (Rajavashisth  et  al.,  1990),  and 
GM-CSF down-regulates serum cholesterol while up-regulating 
VLDL receptor mRNA expression (Ishibashi et al., 1994b). 
GM-CSF deficiency has variable effects on mouse atheroscle-
rosis. In Ldlr/ mice, lesions were decreased (Shaposhnik   
et al., 2007), whereas in Apoe/ mice they were increased 
(Ditiatkovski et al., 2006). Because the majority of proliferat-
ing cells in early lesions are CD11c+ (Fig. 3) and GM-CSF 
deficiency  results  in  decreased  CD11c+  cells  in  lesions   
(Shaposhnik et al., 2007), we investigated whether GM-CSF 
regulates cell proliferation in atherosclerotic lesions.
Initial  experiments  used  real-time  PCR  to  investigate 
mRNA expression of the GM-CSF receptor  chain (GMR) 
in 2-wk-old lesions of Ldlr/ mice. GMR is specific for 
GM-CSF, unlike the  chain that is shared by IL-3 and IL-5 
(Rosas et al., 2007). The LC intima of the ascending aortic 
arch, which contains lesions, was compared with the non-
diseased greater curvature (GC), a region that is protected from 
atherosclerotic  lesion  development.  Expression  of  GMR 
was markedly elevated in lesions relative to the uninvolved 
GC intima (Fig. 5 a). There was also enrichment of DCs and 
myeloid cell markers (CD11c and CD68) in lesions, but ex-
pressions of T cell (CD3), smooth muscle cell (SM22), and 
endothelial cell (CD31 and intercellular adhesion molecule 2) 
markers were comparable. Having established that GMR is 
expressed in 2-wk lesions, two complementary experiments 
directly evaluated the role of GM-CSF in intimal cell prolif-
eration. Injection of mouse GM-CSF increased the abun-
dance of BrdU+ nuclei by 2.7-fold in 2-wk intimal lesions 
(Fig. 5 b), indicating that many cells in lesions are capable of 
proliferating after exposure to GM-CSF. In this experiment, 
BrdU+ leukocytes were not detected in the circulation. In-
jection of a function-blocking antibody to GM-CSF reduced 
the number of proliferating cells in lesions by 4.8-fold (Fig. 5 c). 
Collectively, our data demonstrate that GM-CSF is critical 
for intimal cell proliferation in early lesions.
Germline genetic manipulations in mouse models are 
used to investigate molecular atherogenic mechanisms, yet 
analysis of atherosclerotic lesions in mice typically consists 
of lesion burden assessment (by staining for accumulated 
intimal  lipid)  and  evaluation  of  cell/matrix  composition   
using histological approaches. Leukocyte recruitment and 
intimal cell proliferation or death can independently result 
in differences in lesion burden. This study illustrates a prac-
tical, sensitive, and reproducible approach for quantifying 
cellular events in atherosclerosis. BrdU pulse labeling com-
bined with en face confocal microscopy provides quantita-
tive  information  on  intimal  cell  proliferation,  as  well  as 
recruitment of Ly-6Chigh blood monocytes within a 24-h 
window. Using this approach, we showed that proliferation 
of intimal cells and recruitment of BM-derived Ly-6Chigh 
monocytes increase progressively from the inception of ath-
erosclerosis. Experiments with PTx suggested that the two 
processes occur independently of each other and raise the 
possibility that blockade of recruitment or proliferation in-
dividually may result in a compensatory response. Thus, 
for effective therapy it may be necessary to target both pro-
cesses. Previously, GM-CSF was reported to function in the 
differentiation of monocytes to DCs (Chapuis et al., 1997; 
Daro et al., 2000) and in the proliferation of mouse DC 
precursors (Inaba et al., 1992). Our current data support 
an important role for GM-CSF in mediating intimal DC 
proliferation in early atherosclerotic lesions and suggest that 
it may be prudent to block functions of this cytokine when 
administering a therapy for early atherosclerosis that targets 
monocyte recruitment.2148 CELL PROLIFERATION DURING ATHEROGENESIS | Zhu et al.
using FlowJo analysis software (version 7.2.2; Tree Star, Inc.). A hemo-
cytometer (Bright-Line; Hausser Scientific) was used to determine the con-
centration of blood leukocytes.
En face confocal microscopy of aortas from BrdU-injected mice. 
Aortas were harvested after perfusion fixation (4% paraformaldehyde, 100 
mmHg), and the surrounding adipose tissue was dissected after further fixation 
for 1 h. For detection of BrdU-labeled intimal cells, aortas were permeabilized 
(0.5% Triton X-100 for 15 min) and incubated sequentially with 0.3% H2O2 
(30 min), DNase I (1.5 h at 37°C), FITC-conjugated anti-BrdU (18 h at 4°C), 
horseradish peroxidase (HRP)–conjugated anti-FITC (1:300 dilution for 1 h; 
Abcam), and FITC-tyramide (PerkinElmer). Lipid accumulated in lesions was 
detected by oil red O (Sigma-Aldrich) staining (Lichtman et al., 1999), and 
nuclei were counterstained with 2 µg/ml Hoechst 33342 (Invitrogen).
For immunophenotyping of BrdU+ cells, aortas were incubated over-
night with FITC–anti-BrdU and biotinylated mAb to CD11b (BD), CD11c, 
CD45 (eBioscience), 33D1 (BD), or CD68 (AbD Serotec). mAbs to CD11b, 
CD11c, and CD45 were detected with streptavidin-HRP (1:300 dilution) 
and cyanine 3–tyramide (PerkinElmer), and others were detected with strep-
tavidin-PE. PE–anti–MHC II (BD) and Alexa Fluor 647–anti-CD11c (Bio-
Legend) were also used. A confocal microscope (FV-1000; Olympus) with a 
60× (NA 1.4) oil objective was used to acquire images.
Real-time PCR. Enzymatic harvesting of intimal cells, reverse trans-
cription real-time PCR (SYBR green– or FAM-labeled GM-CSF2R 
TaqMan MGB probe; Mm00438331_g1; ABI Prism 7900HT; Applied 
Biosystems), and normalization of data were performed as previously de-
scribed (Jongstra-Bilen et al., 2006).
Statistical analyses. Differences between two groups were determined by 
an unpaired two-tailed t test and analysis of variance followed by Tukey-
Kramer multiple comparison tests were used to compare multiple groups.
Online supplemental material. Fig. S1 shows the location of proliferating 
intimal BrdU+ cells (a–c), and the time course of proliferating BrdU+ nu-
clei and BrdU+ nuclear doublets (d–f) in 2-wk lesions. Fig. S2 depicts flow 
cytometry analysis of the peritoneal exudates and blood of PTx-treated and 
control mice. Fig. S3 shows the distribution of BrdU+CD11c+ proliferat-
ing intimal cells costained with CD68 or CD11b in 2-wk lesions. Fig. S4 
depicts costaining of BrdU+CD11c+ proliferating intimal cells with MHC II   
and CD68. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090866/DC1.
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